Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies
about
Toxicity of infliximab in the course of treatment of Crohn's disease.A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents.SD0006: a potent, selective and orally available inhibitor of p38 kinase.Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders.
P2860
Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Recent developments in the use ...... rs. The role of autoantibodies
@ast
Recent developments in the use ...... rs. The role of autoantibodies
@en
type
label
Recent developments in the use ...... rs. The role of autoantibodies
@ast
Recent developments in the use ...... rs. The role of autoantibodies
@en
prefLabel
Recent developments in the use ...... rs. The role of autoantibodies
@ast
Recent developments in the use ...... rs. The role of autoantibodies
@en
P2860
P356
P1433
P1476
Recent developments in the use ...... rs. The role of autoantibodies
@en
P2093
Silja Rott
Ulrich Mrowietz
P2860
P304
P356
10.1136/BMJ.330.7493.716
P407
P577
2005-03-01T00:00:00Z